Back to News
Market Impact: 0.2
Eledon Announces Updated BESTOW Long-Term Data, Wins FDA Fast Track Designation For Tegoprubart
Source: Nasdaq
Healthcare & Biotech
Eledon Pharmaceuticals announced updated long-term data from its Phase 2 BESTOW clinical program evaluating tegoprubart in kidney-transplant patients. The article provides no efficacy, safety, or financial details, limiting the immediate assessment of the program's clinical or valuation impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
ELDN0.45
More News
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Apollo-backed dental firm vVardis seeks up to $229 million in US IPO
- Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity drugs
- Jefferies raises Inovio stock price target on regulatory win
- Humana lifts annual profit forecast as medical costs ease
- Truist raises Vericel stock price target on MACI growth momentum